Search
Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.
Dalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalThis is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Lactose
go.drugbank.com/drugs/DB04465ApprovedInvestigationalWithdrawnA disaccharide of glucose and galactose in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.
Categories: Compounds used in a research, industrial, or household settingLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115]
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials.
Inotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigationalInotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects
Sertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. … It is a phenylindole derivative used in the treatment of schizophrenia.
Besilesomab
go.drugbank.com/drugs/DB13979ApprovedBesilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Hydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. … [A1257,A187589] It was first developed in 1955,[A189726] and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus